Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from CureVac ( (CVAC) ).
On June 24, 2025, CureVac N.V. held its annual general meeting of shareholders, where several key resolutions were passed. The shareholders approved the adoption of the 2024 annual accounts, released managing and supervisory directors from liability for the previous financial year, and appointed new members to the management and supervisory boards. Additionally, the meeting authorized the management board to issue shares, limit pre-emption rights, and amend supervisory board compensation. These decisions reflect a strategic alignment and governance strengthening, potentially enhancing CureVac’s operational capabilities and stakeholder confidence.
The most recent analyst rating on (CVAC) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on CureVac stock, see the CVAC Stock Forecast page.
Spark’s Take on CVAC Stock
According to Spark, TipRanks’ AI Analyst, CVAC is a Outperform.
CureVac’s overall stock score reflects strong financial improvements and an attractive valuation. Technical analysis indicates bullish momentum, although the RSI suggests caution. The historical volatility in financial metrics remains a potential risk.
To see Spark’s full report on CVAC stock, click here.
More about CureVac
CureVac N.V. is a biotechnology company based in Tübingen, Germany, primarily focused on developing mRNA-based therapies and vaccines. The company operates within the pharmaceutical and biotechnology industry, with a strong emphasis on innovative treatments and preventive solutions.
Average Trading Volume: 1,179,175
Technical Sentiment Signal: Buy
Current Market Cap: $1.22B
Find detailed analytics on CVAC stock on TipRanks’ Stock Analysis page.